DSM-Firmenich

Temporary vitamin effect lasts longer

02/05/25 -"dsm-firmenich commenced the year as anticipated, aligning closely with consensus expectations (sales: -0.2%; adjusted EBITDA: -0.7%; temporary vitamin effect: -8.7%). The significant deviation in the ..."

PDF page sample
Pages
68
Language
English
Published on
02/05/25
Download
You may also be interested by these reports :
02/05/25
The firm reported Q1 results that exceeded consensus expectations (sales: +5.4%; EBITDA: 0.0%; EBIT: reported €14.9m; expected: -4.7m). While ...
02/05/25
dsm-firmenich commenced the year as anticipated, aligning closely with consensus expectations (sales: -0.2%; adjusted EBITDA: -0.7%; temporary ...
02/05/25
Remaining on track for FY25 guidance – Worthwhile waiting for 2Q25E
30/04/25
1Q25 7% below consensus expectations, run-rate below lower guidance end

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO